Table 2

Summary of adverse events in patients receiving ≥1 onabotulinumtoxinA treatment

AE, n (%)Safety population (N=716)
Any AE
 ≥1 AE436 (60.9)
 Serious AE75 (10.5)
 AE in those who discontinued treatment32 (4.5)
Treatment-related AE
 ≥1 treatment-related AE131 (18.3)
 Serious treatment-related AE1 (0.1)
 Treatment-related AE in those who discontinued treatment13 (1.8)
Treatment-related AE with incidence ≥1%
 Neck pain29 (4.1)
 Eyelid ptosis18 (2.5)
 Musculoskeletal stiffness17 (2.4)
 Injection site pain14 (2.0)
 Headache12 (1.7)
 Muscular weakness10 (1.4)
 Facial paresis9 (1.3)
 Migraine7 (1.0)
 Skin tightness7 (1.0)